Page last updated: 2024-11-12
nidulalin a
Description
nidulalin A: antitumor dihyhroxanthone derivatives isolated from Penicillium sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
nidulalin A : A member of the class xanthones which consists of a dihydroxanthone skeleton substituted by hydroxy groups at positions 4 and 8, a methyl group at position 6 and a methoxycarbonyl group at position 4a (the 4R,4aS stereoisomer). It is isolated from Emericella nidulans var lata and Penicillium and exhibits potent antitumour activity against both human and murine tumour cell lines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (10)
| Synonym |
|---|
| chebi:66625 , |
| CHEMBL91382 , |
| MEGXM0_000109 |
| (4r,4as)-4,8-dihydroxy-6-methyl-9-oxo-4,9-dihydro-xanthene-4a-carboxylic acid methyl ester |
| bdbm50081427 |
| nidulalin a |
| methyl (4r,4as)-4,8-dihydroxy-6-methyl-9-oxo-4,9-dihydro-4ah-xanthene-4a-carboxylate |
| f390 |
| methyl (4r,4as)-4,8-dihydroxy-6-methyl-9-oxo-4h-xanthene-4a-carboxylate |
| Q27135244 |
Roles (3)
| Role | Description |
|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| Penicillium metabolite | Any fungal metabolite produced during a metabolic reaction in Penicillium. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| xanthones | Any member of the class of xanthenes based on a xanthone skeleton. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (2)
Inhibition Measurements
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID211314 | In vitro inhibitory activity against topoisomerase II (Topo II) by using decatenation assay | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| AID150526 | In vitro cytotoxic activity against murine cancer cell line P388 by using MTT assay | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| AID211096 | In vitro inhibitory activity against topoisomerase I (Topo I) by using relaxation assay | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| AID110695 | In vivo antitumor activity against Colon 26 murine tumor model at a dose of 20 mg/kg administered intravenously | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| AID80687 | In vitro cytotoxic activity against human cancer cell line HCT116 by using MTT assay | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| AID94807 | In vitro cytotoxic activity against human cancer cell line K562 by using MTT assay | 1999 | Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
| Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.60 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.39 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |